First-Ever Serology Test Built on Multiparameter Flow Cytometry Platform Differentiates Between COVID-19 Infection and Vaccination Antibodies

A novel test can measure and track an individual's immune response to the COVID-19 vaccine, now and over time.

FlowMetric Life Sciences Inc. (Doylestown, PA, USA) has launched VaxEffect COVID-19 Vaccine Immune Response Test which will provide a personalized, and clinically accurate readout of a person's COVID-19 specific antibody levels, either generated in response to the COVID-19 vaccine or to prior exposure to the SARS-CoV-2 virus. With simple, repeat testing, changes in these antibody levels can be tracked over time utilizing easy-to-read longitudinal reports, to better inform vaccine-based healthcare decisions and to support the optimal use of booster vaccinations as they become available.

Unlike other antibody tests, VaxEffect is the first COVID serology test built on a multiparameter flow cytometry platform that is designed to differentiate between infection and vaccination based on an antibody profile. Using this proven, powerful, and precise technology, the VaxEffect Test is both 99%+ sensitive and 99%+ specific.

"The VaxEffect test will be especially important for patients with immune compromised conditions such as those fighting cancer, diabetes, auto-immune disorders, or those that are immunosuppressed due to organ transplantation, who may have not generated a strong immune response to the vaccine," said Grant Morgan, Ph.D., General Manager of VaxEffect and EVP of FlowMetric Life Sciences Inc.

Related Links:
FlowMetric Life Sciences Inc.